Psoriasis Pso clinical trials

Explore recruiting psoriasis pso clinical trials.

Recruiting psoriasis pso studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Psoriasis Pso trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

Poland, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 3B exploratory multicenter open-label study to evaluate the effect of bimekizumab on gene expression biomarkers in study participants with moderate to severe plaque psoriasis.

Poland, Germany

Phase III and phase IV (Integrated) EU CTIS Study details

A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB COMPARED TO USTEKINUMAB IN CHILDREN AND ADOLESCENT FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Germany, Belgium, Czechia, Spain, Italy, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-label, randomized, assessor-blinded, efficacy, safety, tolerability, and pharmacokinetics study of subcutaneous risankizumab with an adalimumab reference arm in children with active juvenile psoriatic arthritis

Poland, Spain, France, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)

Spain, Germany, Czechia, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

Czechia, Germany, Estonia, Spain, Slovakia, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Psoriasis Pso trials by city

Psoriasis Pso in Toronto Psoriasis Pso in Vancouver Psoriasis Pso in Montreal Psoriasis Pso in Calgary Psoriasis Pso in Edmonton Psoriasis Pso in Ottawa Psoriasis Pso in Winnipeg Psoriasis Pso in Quebec City Psoriasis Pso in Hamilton Psoriasis Pso in Kitchener Psoriasis Pso in London Psoriasis Pso in Halifax Psoriasis Pso in New York Psoriasis Pso in Los Angeles Psoriasis Pso in Chicago Psoriasis Pso in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease